AmeReGen-GC Arabia SP is a privately held segregated portfolio corporation of investment portfolio and HQ management services firm AmeReGen BioPharmaceuticals INC SPC, and the exclusive distributor of the entire breakthrough stem cell drug class of CITA for cancer. It imports premium and pharmaceutical grade, highly quality-assured adult stem cell products sourced from a network of proprietary pharmaceutical grade and scale manufacturers. We are exclusive to the entire region of the Arabic Gulf States, and partner only with the best medical centres.

AmeReGen-GC Arabia SP is currently conducting a global partnering search to determine powerful, ethical, and respected distributorship JV partners for CITA product exports to GC Arabia and to create one premium HCC liver cancer center of excellence for the entire region. Such JV needs to meet strong global and GC Arabic demand for gentler yet better cancer therapeutics. 

AmeReGen-GC Arabia SP has secured globally exclusive manufacturing rights related to an entire, new, and fully market launched oncology "drug" class called Cellular Intravascular Targeting Agents, CITA. Company's lead product, CITA Cell Pak™ treats in eligible advanced patients with otherwise lethal primary liver cancer HCC and metastatic and drug-resistant problem liver cancers from many kinds of primary cancers including all four stages. 

We have the world's longest (since 2004) objective clinical success as a fully approved routine CITA cell program with virtually no side effects in any of our routine applications. Subspecialty  manufactures will ship CITA Cell Pak™ for various national distributors within the AmeReGen BioPharmaceuticals SPC Consortium of leading (stem) cell companies. We are planning to set up the largest and academically most advanced such distributorship and partnership with the leading medical centre of the region TBD and as early as mid 2011. Such top medical centre will fully appreciate our exclusive offerings of our quasi-robotic mass-manufactured, highest standardized QA/AC stem cell product definitions in the industry for treatment programs and the prestige of medically publishing the NEXT breakthrough in liver cancer as coming from Arabia to the world.

CITA PURGE Transplants are technology-related to adult (ethical, hematopoietic) stem cell transplantation, yet as their newest generation procedures do no longer require patients to undergo chemo- or radiation treatments, and are beyond clinical trials for almost a decade, and approved and launched in the FRG within the EU since 2004.